1.
S3 Fig -
2.
3.
4.
5.
S4 Fig -
S5 Fig -
S6 Fig -
CBP per cumulative year for daratumumab and pembrolizumab per vial.
CBP per cumulative indication for daratumumab and pembrolizumab per vial.
Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.
Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.
Implementation of indication-based pricing (10 th scenario) for daratumumab and pembrolizumab.
Input parameters for the base-case analysis.